UCB S.A. (UCBJF)
OTC PINK OTC PINK Primary Summary
United Community Banks, Inc. (UCB) Q3 2025 Earnings Call Transcript
United Community Banks, Inc. (NYSE:UCB ) Q3 2025 Earnings Call October 22, 2025 9:00 AM EDT Company Participants Herbert Harton - Chairman & CEO Jefferson Harralson - Executive VP & CFO Richard Bradshaw - President & Chief Banking Officer Robert Edwards - Executive VP & Chief Risk Officer Conference Call Participants Stephen Scouten - Piper Sandler & Co., Research Division Gary Tenner - D.A. Davidson & Co., Research Division Michael Rose - Raymond James & Associates, Inc., Research Division Russell Elliott Gunther - Stephens Inc., Research Division Catherine Mealor - Keefe, Bruyette, & Woods, Inc., Research Division Kyle Gierman Presentation Operator Good morning and welcome to United Community Banks' Third Quarter 2025 Earnings Call.
United Community Banks (UCB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for United Community Banks (UCB) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
United Community Banks (UCB) Surpasses Q3 Earnings and Revenue Estimates
United Community Banks (UCB) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to earnings of $0.57 per share a year ago.
UCB S.A. (UCBJF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has UCB S.A. ever had a stock split?
UCB S.A. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Mr. Hiroyuki Kawamoto CEO | OTC PINK Exchange | BE0003739530 ISIN |
| Japan Country | 689 Employees | 28 Apr 2025 Last Dividend | - Last Split | - IPO Date |
Overview
UCB SA is a global biopharmaceutical company with a focus on discovering and developing innovative therapies for neurology and immunology diseases. Founded in 1925 and headquartered in Brussels, Belgium, UCB has established itself as a leader in the field of biopharmaceutical research, offering a range of products aimed at improving the lives of patients across the world. The company's dedication to addressing unmet medical needs is evidenced by its robust pipeline of treatments in various stages of development, as well as its strategic partnerships with industry leaders like Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. UCB also participates in contract manufacturing activities, leveraging its expertise to support other entities within the pharmaceutical sector.
Products and Services
UCB SA provides a diverse portfolio of products and services designed to meet the therapeutic needs of patients with neurological and immunological conditions. These include:
- Cimzia: A treatment for a variety of inflammatory diseases mediated by TNF, including ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.
- Vimpat, Keppra, and Briviact: A group of medications aimed at managing epilepsy.
- Neupro: Designed for the treatment of Parkinson's disease and restless legs syndrome.
- Nayzilam: A nasal spray rescue treatment for epilepsy seizure clusters.
- Zyrtec and Xyzal: Medications for alleviating allergies.
- Evenity: A treatment for osteoporosis in postmenopausal women.
- Bimzelx: A biologic approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
- Fintepla: Developed for the treatment of Dravet syndrome, a rare and severe form of epilepsy.
- Rozanolixizumab and Zilbrisq: Currently in development for treating myasthenia gravis, an autoimmune disease that affects muscle strength.
- Dapirolizumab pegol: An investigational treatment for systemic lupus erythematosus.
- Fenfluramine: Aimed at treating CDKL5 deficiency disorder and other rare forms of epilepsy.
- Doxecitine: In development for TK2 deficiency disorder, a genetic disorder affecting the muscle.
- STACCATO Alprazolam: A candidate for treating stereotypical prolonged seizures.
- Bepranemab: Under research for Alzheimer's disease therapy.
- Minzasolmin and UCB0222: Targets for Parkinson's disease treatment.
- UCB1381 and UCB9741: In development for treating atropic dermatitis, an inflammatory skin condition.
Contact Information
